Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423446 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL423445 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8653995 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8948482 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Hydrochloric Acid SCHEMBL15779291 | 0.97 | AKR1B1 (0.36) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Phosphoric Acid SCHEMBL5789491 | 0.91 | MPI (0.39) | AKR1B1LMNAL3MBTL1MPI | |
| SCHEMBL5699947 | 0.85 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL17984936 | 0.85 | HIF1A (0.41) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL17984952 | 0.85 | LMNA (0.46) | AKR1B1LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL17984927 | 0.84 | THRB (0.33) | AKR1B1HIF1AMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5510470-A | CONTAINS A DIDEOXYSACCHARIDE; USED WITH ZERO VALENT NICKEL AS A CATALYST FOR ENANTIOSELECTIVE HYDROCYANATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | claimed |
| US-5484902-A | HYDROCYANATION OF VINYL AROMATICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-16 | — | — | US | claimed |
| CN-119907682-A | Development of carbohydrate-based anti-salmonella vaccines | 密西根州立大学校董会 | 2025-04-29 | — | — | CN | disclosed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| CN-117843740-A | Transcription factor AcaR, gene and recombinant bacterium derived from actinoplanes, and preparation methods and applications thereof | 安徽工程大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-114728053-A | Immunogenic compositions against intestinal disease and process for preparing same | 印度血清研究所私人有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| WO-1998053851-A1 | LAFT MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0876150-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1998-11-11 | — | — | EP | disclosed |
| CN-1172161-A | Acarviosyl transferase and preparation and application thereof | BAYER AG (DE) | 1998-02-04 | — | — | CN | disclosed |
| WO-1997019688-A9 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997019688-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1997-06-05 | — | — | WO | disclosed |
| US-5510470-A | CONTAINS A DIDEOXYSACCHARIDE; USED WITH ZERO VALENT NICKEL AS A CATALYST FOR ENANTIOSELECTIVE HYDROCYANATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-4696916-A | Intravenous nutrient | UNITIKA LTD. (JP) | 1987-09-29 | — | — | US | disclosed |
| EP-0100382-B1 | AN INTRAVENOUS NUTRIENT | UNITIKA LTD. (JP) | 1986-11-20 | — | — | EP | disclosed |
| EP-0100382-A1 | An intravenous nutrient | UNITIKA LTD. (JP) | 1984-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885LMNA 1219/4885L3MBTL1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.